Publications by authors named "Lorna MacLean"

Claim this Profile
S
Structure-activity relationships of 1,5-dihydro-2-benzo[][1,4]diazepine-2,4(3)-diones as inhibitors of .
Michael G Thomas, Joanne Dunne, Peter G Dodd, Emiliana D'Oria, Laura Frame, Lorna MacLean

RSC Med Chem· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacological and structural understanding of the Trypanosoma cruzi proteasome provides key insights for developing site-specific inhibitors.
Thomas C Eadsforth, Leah S Torrie, Paul Rowland, Emma V Edgar, Lorna M MacLean

J Biol Chem· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation of Trypanosoma cruzi inactivation techniques for laboratory use.
Lorna M MacLean, Mark Ariyanayagam, Lalitha Sastry, Christy Paterson, Manu De Rycker

PLoS One· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of a potent and selective LAPTc inhibitor by RapidFire-Mass Spectrometry, with antichagasic activity.
Maikel Izquierdo, De Lin, Sandra O'Neill, Lauren A Webster, Christy Paterson, Lorna MacLean

PLoS Negl Trop Dis· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RES-Seq-a barcoded library of drug-resistant allowing rapid assessment of cross-resistance and relative fitness.
Lindsay B Tulloch, Sandra Carvalho, Marta Lima, Richard J Wall, Michele Tinti, Lorna MacLean

mBio· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Short-course combination treatment for experimental chronic Chagas disease.
Silvia González, Richard J Wall, John Thomas, Stephanie Braillard, Gino Brunori, Lorna MacLean

Sci Transl Med· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-Guided Design and Synthesis of a Pyridazinone Series of Proteasome Inhibitors.
Michael G Thomas, Kate McGonagle, Paul Rowland, David A Robinson, Peter G Dodd, Lorna MacLean

J Med Chem· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Cyclin-dependent kinase 12 is a drug target for visceral leishmaniasis.
Susan Wyllie, Michael Thomas, Stephen Patterson, Sabrinia Crouch, Manu De Rycker, Lorna M MacLean

Nature· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of a Proteasome-Targeting Arylsulfonamide with Potential for the Treatment of Chagas' Disease.
Marta L Lima, Lindsay B Tulloch, Victoriano Corpas-Lopez, Sandra Carvalho, Richard J Wall, Lorna MacLean

Antimicrob Agents Chemother· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of 6-amino-1-pyrazolo[3,4-]pyrimidines with efficacy against visceral leishmaniasis.
Michael G Thomas, Manu De Rycker, Myriam Ajakane, Sabrinia D Crouch, Lorna Campbell, Lorna MacLean

RSC Med Chem· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Q Site of Cytochrome is a Promiscuous Drug Target in and .
Richard J Wall, Sandra Carvalho, Rachel Milne, Juan A Bueren-Calabuig, Sonia Moniz, Lorna MacLean

ACS Infect Dis· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical candidate for the treatment of visceral leishmaniasis that acts through proteasome inhibition.
Susan Wyllie, Stephen Brand, Michael Thomas, Manu De Rycker, Chun-Wa Chung, Lorna MacLean

Proc Natl Acad Sci U S A· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of GSK3186899/DDD853651 as a Preclinical Development Candidate for the Treatment of Visceral Leishmaniasis.
Michael G Thomas, Manu De Rycker, Myriam Ajakane, Sébastian Albrecht, Ana Isabel Álvarez-Pedraglio, Lorna MacLean

J Med Chem· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cyclin-dependent kinase 12 is a drug target for visceral leishmaniasis.
Susan Wyllie, Michael Thomas, Stephen Patterson, Sabrinia Crouch, Manu De Rycker, Lorna M MacLean

Nature· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of Trypanosoma cruzi in vitro assays to identify compounds suitable for progression in Chagas' disease drug discovery.
Lorna M MacLean, John Thomas, Michael D Lewis, Ignacio Cotillo, David W Gray

PLoS Negl Trop Dis· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploring the Leishmania Hydrophilic Acylated Surface Protein B (HASPB) Export Pathway by Live Cell Imaging Methods.
Lorna MacLean, Helen Price, Peter O'Toole

Methods Mol Biol· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chemical Validation of Methionyl-tRNA Synthetase as a Druggable Target in Leishmania donovani.
Leah S Torrie, Stephen Brand, David A Robinson, Eun Jung Ko, Laste Stojanovski, Lorna MacLean

ACS Infect Dis· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and Optimization of 5-Amino-1,2,3-triazole-4-carboxamide Series against Trypanosoma cruzi.
Stephen Brand, Eun Jung Ko, Elisabet Viayna, Stephen Thompson, Daniel Spinks, Lorna MacLean

J Med Chem· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The relationship of endotoxaemia to peripheral and central nervous system inflammatory responses in Human African Trypanosomiasis.
Lorna Maclean, Eltayb A Aboubaker, Peter G E Kennedy, Jeremy M Sternberg

Parasitology· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population genetics of Trypanosoma brucei rhodesiense: clonality and diversity within and between foci.
Craig W Duffy, Lorna MacLean, Lindsay Sweeney, Anneli Cooper, C Michael R Turner

PLoS Negl Trop Dis· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Stage progression and neurological symptoms in Trypanosoma brucei rhodesiense sleeping sickness: role of the CNS inflammatory response.
Lorna MacLean, Hansotto Reiber, Peter G E Kennedy, Jeremy M Sternberg

PLoS Negl Trop Dis· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The orthologue of Sjögren's syndrome nuclear autoantigen 1 (SSNA1) in Trypanosoma brucei is an immunogenic self-assembling molecule.
Helen P Price, Michael R Hodgkinson, Rachel S Curwen, Lorna M MacLean, James A Brannigan

PLoS One· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trafficking and release of Leishmania metacyclic HASPB on macrophage invasion.
Lorna M Maclean, Peter J O'Toole, Meg Stark, Jo Marrison, Claudia Seelenmeyer

Cell Microbiol· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Focus-specific clinical profiles in human African Trypanosomiasis caused by Trypanosoma brucei rhodesiense.
Lorna M MacLean, Martin Odiit, John E Chisi, Peter G E Kennedy, Jeremy M Sternberg

PLoS Negl Trop Dis· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Leishmania-specific surface antigens show sub-genus sequence variation and immune recognition.
Daniel P Depledge, Lorna M MacLean, Michael R Hodgkinson, Barbara A Smith, Andrew P Jackson

PLoS Negl Trop Dis· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis